课题基金 / 基金详情

Oncolytic immunotherapy-driven synthetic lethality for Breast Cancer

Oncolytic immunotherapy-driven synthetic lethality for Breast Cancer
溶瘤免疫疗法驱动的乳腺癌综合致死率
批准号：
457642
负责人：
Jamalkhah Choshali Monire
金额：
$10.93万
依托单位：
University of Ottawa
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-11-01 至 2024-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=457642&lang=en
关键词：
Brca Mutation-Bearing Breast Cancer Immunotherapy Of Cancer In Situ Production Of Mirna-Loaded Exosoms Oncolytic Virotherapy Restoration Of Drug Resistance Small Inhibitory Rna Technique To Down-Regulate Genes Synthetic Lethality

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Breast Cancer is the second most common cancer in Canada and the most common cancer among Canadian females. Poly(ADP-ribose) polymerase inhibitors have been approved by Food and Drug Administration for cancers with faults in one of the BRCA genes. But des
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金